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Abstract 
Data from the Australasian Bone Marrow Transplant Recipient Registry show a steady 
increase in the number of allogeneic haemopoietic stem cell transplantations (HSCT) 
performed annually in Australia and New Zealand. In 2012, 629 allogeneic HSCT were 
performed. Allogeneic HSCT is associated with numerous potential complications, 
including chronic graft-versus-host disease (cGVHD). The oral cavity is one of the most 
frequent sites affected by cGvHD, often leading to significant disability and reduced 
quality of life. Management strategies are often complex, of variable efficacy and 
influenced by the availability of various therapeutic agents, access to compounding 
pharmacies and associated costs. This paper summarises the current status of allogeneic 
HSCT in Australia and New Zealand with a focus on oral cGvHD and the associated 
challenges in its management. 
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Introduction 
Allogeneic haemopoietic stem cell transplantation (HSCT), along with the accompanying 
immunosuppression, is associated with several, potentially debilitating, long-term 
complications, one of the most significant being chronic Graft-versus-Host Disease (cGvHD). 
Chronic GvHD is a multisystem immune disorder characterised by immune dysregulation, 
immunodeficiency, impaired organ function and decreased survival1. Nearly 50% of patients 
who survive longer than 1-year after HSCT develop cGvHD2. Factors influencing the risk of 
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cGVHD onset overall include the use of mobilised peripheral blood stem cells as opposed to 
bone marrow as the graft source, older donor and patient age and the use of unrelated 
donors3. All of these factors are increasingly common in HSCT practice internationally and will 
likely result in increased presentations of oral cGVHD. Specific risk factors for the development 
of oral cGvHD are less well established with the use of peripheral blood stem cells and a prior 
history of aGvHD identified in the literature4.  
 
Management of cGvHD remains a significant challenge. One of the most frequent sites 
affected by cGvHD is the oral cavity which may be the primary or sole site of involvement5; 
Oral cGVHD has a significant and detrimental impact on oral health, function and quality of 
life. 
 
Therapeutic decisions in the management of oral cGvHD must consider the patient’s global 
disease status and requires close liaison with the patient’s transplant physician. Critically, data 
is scarce on the efficacy of the commonly utilised topical and systemic agents in the 
management of oral cGvHD with the effectiveness of these agents presumed by extrapolating 
from their effectiveness in the management of more common, immune mediated mucosal 
diseases such as oral lichen planus. Management strategies vary between transplant centres 
and are often based on institutional practice and influenced by the availability of particular 
agents and formulations, patient acceptance and cost6.  
 
Allogeneic HSCT in Australia 
Allogeneic HSCT has evolved as a curative therapy for haematological malignancy, bone 
marrow failure, immune deficiencies and some solid tumours. The Australasian Bone Marrow 
Transplant Recipient Registry has a comprehensive database of transplant activity since 1992. 
Registry figures demonstrate a steady annual growth in the number of allogeneic HSCT 
performed in Australia and New Zealand. A total of 570 allogeneic transplants were 
undertaken in 2013, representing an increase of 16% over a 5-year period7. The most common 
indication for allogeneic transplantation in Australia and New Zealand, as it is internationally, is 
acute myeloid leukaemia in both the related donor (34%) and unrelated donor (35%) 
transplant setting7,8 
 
Graft-versus-Host Disease is a common transplant-associated complication following 
allogeneic HSCT, second only to infection. Severe cGvHD is the primary cause for transplant-
related mortality (TRM) and is the main contributor to the development of life-threatening 
opportunistic infection post-HSCT.  
 
The Clinical Spectrum and Diagnosis of Oral cGvHD 
The reported incidence of oral cGVHD varies widely with 45-83% of patients who experience 
cGvHD showing features of oral involvement6. Presentations include characteristic lichenoid 
mucosal lesions, xerostomia secondary to salivary gland involvement or a reduction in oral 
aperture, resulting from local sclerodermatous disease of the skin. 
 
Mucosal chronic GvHD 
In 2005-6 the National Institutes of Health (NIH) proposed simplified and standardised criteria 
for the diagnosis and staging of cGvHD9. The range of clinical signs and symptoms seen in 
cGvHD was divided by site or organ involved and each feature assigned to either; 1) those 
deemed to be diagnostic for cGvHD (termed diagnostic features) and 2) those insufficient, 
when arising alone, to secure a diagnosis of cGvHD due to their non-specific nature (termed 
distinctive features). 
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Specific to the oral cavity, the signs and symptoms identified by the NIH consensus papers as 
diagnostic or distinctive for the presence of oral cGvHD are listed in Table 1†. These oral 
mucosal diagnostic features closely resemble, clinically and histologically, common 
autoimmune disorders including scleroderma and oral lichen planus (OLP). Any oral site may 
be affected, however the buccal mucosa, tongue and labial mucosa are most commonly 
affected9.  The degree of involvement may be extensive (Figure 1) and lesions can be a source 
of significant pain, limit nutritional intake and impede overall quality of life10. 
 
Other conditions, common in the transplant patient may bear a resemblance to the clinical 
features of oral cGvHD and potentially lead to a mis-diagnosis of cGvHD. Infections including 
herpetic and fungal, and mucosal trauma are common in the immunocompromised patient, 
especially those suffering from a dry mouth, and may resemble the white plaques and mucosal 
ulceration of oral cGvHD (Figure 2). Simple clinical steps are often sufficient to exclude these 
confounding diagnoses and confirm a diagnosis of oral cGvHD. This may include smoothing of 
sharp teeth in the vicinity of mucosal trauma and using cotton gauze to identify if a white 
patch can be removed, as would be seen in candidosis. However occasionally, particularly in 
the case of persistent oral ulceration, biopsy may be necessary to both confirm the presence 
of oral cGvHD and exclude malignancy. The histopathological features of oral cGvHD have 
been previously well described11.  
  
Salivary hypofunction and xerostomia 
Salivary gland dysfunction arising in the acute stages following allogeneic HSCT is 
predominantly attributable to conditioning regimen toxicity, especially in the case of total 
body irradiation (TBI), and can persist for many months. Late changes are most often ascribed 
to cGvHD and clinically resemble the features of Sjögren syndrome12. Extensive involvement 
results in the total destruction of secretory units leading to permanent and profound salivary 
hypofunction13. Salivary gland dysfunction can be the sole manifestation of oral cGvHD and 
most often presents as the complaint of dry mouth (xerostomia). Critically, the presence of 
salivary hypofunction is not diagnostic for oral cGvHD9 due to the existence of several other 
potential aetiologies, most notably drugs and/or radiotherapy to the head and neck.  
 
Saliva plays a major role in maintaining oral health and oral function. A decrease in the 
quantity or quality of saliva can have a profound effect on the incidence of dental decay, oral 
candidosis, the retention of dentures and mucosal friability as well as an adverse impact on 
speech, swallowing and mastication. Critically, patients report oral dryness as the second most 
distressing symptom both at discharge and at 1 year after allogeneic HSCT14. However, the 
symptom of xerostomia does not always correlate with clinical signs of salivary hypofunction; 
likewise clinical evidence of a reduced salivary flow may be demonstrable in patients who do 
not complain of a dry mouth15.  
 
Clinical Management of Oral Chronic GvHD 
Topical preparations may be the sole therapy for oral cGvHD or may form part of a more 
complex management schedule. The advantages of topical or local therapies include the 
application of intensive treatments without necessarily increasing systemic 
immunosuppression thus maintaining any desirable GVT effects and avoiding systemic 
toxicities and drug interactions6. Critical features of an effective topical or local therapy include 
substantivity (persistence of therapeutic effect), bioavailability when applied to oral mucosa, 
acceptable taste and a non-inhibitory cost.  
                                                        
† All tables and figures are located at the end of this document. 
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The management of oral cGvHD can be divided into: 1) management of oral mucosal changes 
and 2) management of the associated salivary hypofunction. A clinical algorithm for the 
management of symptomatic oral cGvHD is presented in Figure 4. 
 
Management of the oral mucosal lesions of chronic GvHD 
 
Topical corticosteroids 
The mainstay of topical therapy in the management of symptomatic oral cGvHD is steroid 
preparations formulated in a variety of vehicles, including gels, ointments and rinses, and with 
varying potency16. The most commonly used formulations available in Australia are outlined in 
Table 2. 
 
Transient burning and the development of secondary oral candidosis are the most common 
adverse effects of topical corticosteroid therapy. The generalised immunosuppressive and 
anti-inflammatory effects of topical corticosteroids are believed to play the major role in the 
pathogenesis of secondary oral candidosis17.  It has been reported that the presence of oral 
candidosis may lead to an increase in local symptoms18 however this is not universally 
accepted. The development of oral candidosis may delay effective management and obscure 
the original pathology of interest19. Resolution is usually achievable with topical antifungal 
agents18, which are generally prescribed in a prophylactic capacity throughout the course of 
topical steroid therapy.  Several topical antifungal agents are available for use; selection of the 
appropriate vehicle requires consideration of the oral disease status, for example, patients 
with severely dry or ulcerated tissues do not tolerate the use of a lozenge. An antifungal gel is 
usually utilised with miconazole gel (Daktarin Oral Gel) the agent of choice however, 
established drug interactions, especially with warfarin, must be considered (Table 2).  
 
Data demonstrating systemic absorption following application of topical corticosteroids to the 
oral mucosa is lacking; however caution is required in patients with widespread ulceration due 
to reduced mucosal barrier function and with prolonged or excessive use20,21. Unlike the skin, 
oral mucosal atrophy is rarely a significant problem with long-term topical corticosteroid use, 
however for patients with pre-existing mucosal atrophy this may be compounded. For this 
reason, the use of the least potent agent to achieve therapeutic benefit and discontinuation of 
treatment when symptoms resolve is recommended. 
 
Alternate topical agents 
Effective symptom management with topical corticosteroid therapy is not always achievable 
prompting the use of topical immunomodulators. A small number of studies have explored the 
use of topical cyclosporin where oral cGvHD was not responsive to topical corticosteroids. 
Promising results were shown with cyclosporin in both a mouth rinse and adhesive paste, 
however, sample size was insufficient to provide a high level of evidence22,23. Side effects were 
reported as mild and usually consisted of transient burning. While the topical cyclosporine 
mouthwash (Neoral solution) has been utilised in some Australian transplant centres, it is 
prohibitively expensive and so is not routinely used. In addition, it’s unpleasant taste and high 
(12%) ethanol content makes this solution generally not suitable for the frequently ulcerated 
and atrophic presentations of oral cGvHD. 
 
Tacrolimus and pimecrolimus are newer calcineurin inhibitors with an improved safety profile 
in comparison to cyclosporin. In its topical preparation tacrolimus is widely used in the 
treatment of atopic dermatitis and cutaneous cGvHD. There have been promising results when 
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used in the management of symptomatic OLP and the oral mucosal lesions of vesiculobullous 
conditions and Crohns disease, the majority of studies concluding that tacrolimus was at least 
as effective as topical corticosteroids. This has been recently reviewed elsewhere24.  
 
Importantly, tacrolimus ointment has shown success in a limited number of studies in patient’s 
with oral cGvHD25,26. In clinical practice, there is often a preference for the use of topical 
tacrolimus where oral cGvHD involves the lips and vermillion as a means for avoiding the 
potential atrophic effects seen with prolonged topical corticosteroid use in these sites. The use 
of topical tacrolimus in the management of oral mucosal disease has been shown to have 
reasonable safety and few adverse effects with those documented including the sensation of 
mucosal burning, taste disturbance and mucosal staining24. Systemic absorption, with 
therapeutic trough levels, have been reported by some27 however it is unclear if whole blood 
tacrolimus levels need to be continuously assessed in patients receiving topical tacrolimus 
alone, although patients receiving concurrent systemic tacrolimus should be closely 
monitored. 
  
While tacrolimus ointment generally has an acceptable toxicity profile, the United States Food 
and Drug Administration (FDA) issued a “black box” warning for tacrolimus due to a theoretical 
increased risk of malignancy, specifically squamous cell carcinoma (SCC) and lymphoma, when 
used for cutaneous psoriasis28.  In Australia, the use of topical tacrolimus is also inhibited by 
the need for a compounding pharmacist. Ideally tacrolimus is compounded with orabase to 
form a 0.1% ointment. Paraffin wax has been used for skin preparations, however this is not 
suitable for oral use due to poor adhesion. For these reasons, tacrolimus use is limited and 
often restricted to second line therapy when treatment with topical corticosteroids has failed.  
 
Non-pharmacological management strategies form a critical adjunct in the overall 
management of patients suffering from oral mucosal cGvHD. This includes the avoidance of 
known irritants such as sodium-lauryl-sulphate (SLS) containing toothpastes and alcohol-
containing mouthwashes. A bland diet is recommended and often better tolerated with the 
avoidance of spices, chilli and acidic foods during symptomatic phases.  The use of topical 
analgesics, such as lignocaine viscous (2% solution, 15ml swished for 30seconds every 3hours) 
may be helpful when symptomatic oral cGvHD impedes daily activities and nutritional intake.  
 
Management of Xerostomia 
 
Successful management of the symptom of xerostomia associated with cGvHD is often 
enormously challenging. Temporary relief may be achieved through the use of oral 
moisturisers, chewing sugar-free gum, saliva substitutes and frequent sips of water. Artificial 
saliva products are available in various preparations with unique qualities, yet few studies have 
compared their effectiveness. One study compared the efficacy of commercially available 
mucin-based products with carboxymethylcellulose (CMC) preparations – finding that mucin-
containing products were better tolerated and accepted by patients29. Most available 
products, including those in Australia, are, however, CMC preparations, which increase the 
viscosity but do not reproduce the physical or chemical properties of saliva30. Patient 
acceptance of these preparations is also often hindered by taste, viscosity, lubrication 
properties, and poor retention in the mouth31.  
 
Longer lasting results may be seen with the use of sialagogues, such as pilocarpine 
hydrochloride, which directly stimulate the salivary glands to increase output. However, 
functional glandular tissue is required for successful outcomes of therapy. Pilocarpine is most 
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commonly prescribed for the treatment of glaucoma as a locally acting meiotic agent of the 
papillary muscles. Via its cholinergic effect, pilocarpine hydrochloride also increases the 
secretions of exocrine glands including the salivary, lacrimal, sweat and gastric glands along 
with the mucous cells of the respiratory tract. In Australia off label uses of pilocarpine (Isopto 
Carpine eye drops) occurs in numerous conditions associated with salivary hypofunction, 
namely, Sjögren syndrome and more recently salivary hypofunction in cGvHD (Table 3). 
Adverse effects seen with pilocarpine hydrochloride may include urinary urgency and an 
increase in perspiration, lacrimation and nausea. More significant adverse effects include an 
increase in airway resistance and bronchial secretions as well as bradycardia and postural 
hypotension. Pilocarpine should therefore be avoided in patients with significant comorbidities 
including pulmonary or gastrointestinal GvHD.  
 
Several studies have shown promising results with pilocarpine therapy for patients who have 
had head and neck radiotherapy and, more recently, in patients with salivary cGvHD. One 
study demonstrated a statistically significant difference in salivary flow rate 1hour following 
administration of pilocarpine hydrochloride (5mg oral pilocarpine, Salagen™)30. This same 
research also found that saliva levels rapidly returned to baseline following cessation of 
treatment, suggesting that continuous administration is necessary. While longer acting 
sialagogues have been studied in cGvHD (cevimeline-Evoxac™)32 of none these are currently 
available in Australia. Common products used the management of dry mouth are listed in 
Table 3.  
 
Patients should also be encouraged to use a fluoride containing toothpaste that is also SLS 
free, as this is often better tolerated.  Detailed oral hygiene and dietary instruction is also 
essential. Saliva is a reservoir for ions that facilitate tooth remineralisation and so avoidance of 
acidic and sugar-containing foods and beverages are essential in minimising the rampant 
dental decay that is frequently seen in patients with low salivary flow.  
 
Prognosis and Long-Term Screening 
 
Survivors of allogeneic transplantation face a significant risk of secondary malignancies, with 2-
6% of survivors developing a secondary solid malignancy at 10 years33. Squamous cell 
carcinomas of the skin and mouth account for one third of all secondary solid tumours in this 
group with half of these arising within the oral cavity34. Risk factors specific for oral SCC include 
being male, the underlying disease (specifically Fanconi anaemia), a history of cGvHD and total 
body irradiation in the conditioning regimen34,35. The degree of immunosuppression has also 
been investigated as a risk factor for secondary solid tumours35. While both systemic and 
topical immunosuppressive therapy have been suggested as potential risk factors for oral SCC 
exposure to these therapies and the presence of cGvHD are so closely interconnected that it is 
not possible to attribute specific carcinogenic risk33.  
 
Examination and surveillance of the oral tissues of survivors of allogeneic HSCT, with timely 
biopsy of persistent or suspicious lesions to exclude dysplasia or malignancy, should form part 
of the long-term follow-up and screening following transplantation. Ideally this should be 
conducted by experienced Oral Medicine specialists in close collaboration with the bone 
marrow transplant (BMT) team. Guidelines on the long-term management of patients with 
Fanconi anaemia recommend oral mucosal review on a 6 monthly basis while EBMT guidelines 
for long-term follow-up of transplant recipients recommend oral mucosal review annually35,36.  
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Conclusion 
 
Allogeneic transplantation is increasingly used for a range of diseases in children and in adults. 
With improvements in transplantation science, HLA-typing and supportive care more patients 
can anticipate long-term survival following HSCT. Unfortunately, many survivors experience 
chronic GvHD with oral GvHD a major cause of morbidity and a significant determinant of post-
HSCT quality of life. Appropriate management of oral cGvHD is compromised by a paucity of 
good quality evidence but there are guidelines to optimise oral outcome after BMT and these 
should be referenced in all BMT service protocols.  
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Tables and Figures 
 
 
Table 1: Classification of the Signs and Symptoms of Chronic GvHD9 
 Features Description 
Diagnostic Features 
(sufficient to 
establish a diagnosis 
of cGvHD) 
Lichen-type features Fixed, white striations (not removable 
with cotton gauze) 
Hyperkeratotic plaques Fixed, white plaques (not removable 
with cotton gauze) 
Restriction of mouth 
opening from sclerosis 
Fibrosis/hardening of the peri-oral 
tissues on palpation and reduction of 
oral aperture 
 
Distinctive Features 
(insufficient alone to 
establish a diagnosis) 
Xerostomia* The subjective complaint of oral dryness 
Mucocoeles A usually painless, smooth surfaced 
mass. May appear clear or bluish in 
colour and be numerous (Figure 3) 
Mucosal atrophy*  
Pseudomembranes*   
Ulceration*   
Common Features  
(seen in both acute 
and chronic GvHD) 
Gingivitis  
Mucositis  
Erythema  
Pain   
* In all cases, infection, drug effects, malignancy, or other causes must be excluded 
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Table 2: Topical corticosteroids plus common anti-fungals used in the management oral cGvHD  
Potency Generic Name Concentration Brand Instructions for use 
Mild (Class I) 
 Hydrocortisone acetate 1.0% ointment Sigmacort Apply thin film 2-4 times daily after meals 
Moderate(Class II) 
 Triamcinolone acetonide 0.02% ointment  
0.1% emollient 
Aristocort 
Kenalog in 
Orobase 
Apply thin film 2-3 times daily after meals 
 Betamethasone valerate 0.02%, 0.05% 
ointment 
Betnovate  Apply thin layer 2-3 times daily after meals 
 Fluticasone propionate 125cg/dose 
inhaler 
Flixotide 
Metered Dose 
1-2 sprays directed at lesion, 2-4 times daily (max 8 spray doses per day) 
Potent (Class III) 
 Betamethasone valerate 0.1% ointment Betnovate Apply thin film 2-3 times daily after meals 
 Betamethasone diproprionate 0.05% ointment Diprosone Apply thin film 2-3 times daily after meals 
 
Dexamethasone 4mg tablet 0.25mg/ml 
solution 
(0.5mg/rinse) 
1 tablet 
dissolved in 
160ml water 
Gently swish with 20ml for 5min then spit out. Repeat 3-4 times daily 
 
Prednisolone 5mg tablet 0.5% solution Dissolve 1 tablet 
in 10ml water 
Gently swish with entire solution for 5min then spit out. Repeat 3-4 times daily. 
Bitter taste may affect compliance- dexamethasone solution preferred.  
 Mometasonefuroate 0.1% ointment Elocon Apply thin film 1-2 times daily 
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Super potent (Class IV)  
 Betamethasone dipropionate 0.05% OV* Diprosone OV Apply thin film 1-2 times daily 
Intra-lesional injection 
 Triamcinolone acetonide 10mg/ml Kenocort-A 10  Maximum 1mg/injection site, repeat at ≥ 1 week intervals if required 
Commonly used topical antifungals 
 
Miconazole 20mg/g  Daktarin Oral 
Gel 
Place ½ of provided scoop on tongue, hold for as long as possible then swallow. 
Alternatively, patients using an ointment TC can mix both 1:1 
Be aware of drug interactions, especially Warfarin 
 
Nystatin 100 000 U/ml 
(dropper bottle) 
Nilstat Oral 
Drops 
Swirl 1ml in mouth for as long as possible then swallow. Repeat QID 
Alternatively, patients using mouthwash TC can add 1 drop to each mouthrinse. 
Contains sucrose-not for prolonged use in dentate patients 
* OV- optimised vehicle, TC- topical corticosteroids,  
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Table 3: Management of xerostomia in chronic GvHD 
Use Specific agent Main ingredients Instructions for use 
SLS free 
toothpastes 
(fluoride 
containing) 
Biotène Toothpaste  0.14% w/v sodium 
monofluorophosphate 
 
Oral Seven toothpaste 0.76% w/w sodium 
monofluorophosphate 
 
Curasept 
chlorhexidine 
toothpaste 
0.05% fluoride 
0.05% chlorhexidine 
 
Curaprox Enzycal sodium fluoride 950ppm  
Xerostom toothpaste  Sodium fluoride 995ppm Online only 
Sialagogues 4% Isopto Carpin Eye 
Drops (15ml) 
pilocarpine hydrochloride Place 3-4 drops on a spoon, 
stir into a small amount of 
water. Drink solution 
immediately. Repeat 3 times 
daily 
Mucosal 
lubricants 
Biotène Oralbalance 
gel 
Glycerin and sorbitol base  
1. Carbomer 
2. Hydroxyethycellulose 
3. Sodium hydroxide 
Apply on fingertip to affected 
areas when required, 
especially at night. Biotène® 
range: mouthwash, spray 
 
Oral Seven Gel Glycerin, sorbitol base 
1. Aloe barbadensis 
2. Lactoperoxidase 
3. Glucose 
4. Lactoferrin, Lysozyme 
Apply by fingertip to affected 
areas when required, 
especially at night. Oral Seven 
range: mouthwash, spray 
 Hamilton Aquae Oral 
Gel 
Carmellose sodium 20mg/g 
 
PBS approval for 4months in 
palliative care where dry 
mouth is a symptom 
 Hamilton Aquae Liquid Per ml contains: 
Sorbitol solution 42.86mg 
Carmellose sodium10mg 
1-2 sprays into mouth as 
required. PBS approval for 
4months in palliative care  
 
Xerostom® Gel 
(biocosmetic 
laboratories) 
Glycerin based 
Extra virgin olive oil 
Provitamin B5 
Provitamin E 
Parsley oil 
(See fact sheet for full list)  
Apply by fingertip to affected 
areas when required, 
especially at night. Online 
only. Xerostom range: spray, 
pastilles, gum, mouthwash 
 
General salad oils Patients can use any palatable 
salad oil as an oral lubricant 
e.g. coconut oil, olive oil etc 
Place a small amount in 
mouth, use tongue to spread 
over affected tissues 
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Figure 1: Extensive ulceration of oral chronic GvHD 
 
 
 
Figure 2: Patient 6 months post allogeneic HSCT with intra-oral HSV ulceration 
 
 
 
Figure 3: Mucocoeles on the lower labial mucosa of a patient with oral cGvHD 
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Figure 4: Clinical algorithm for symptomatic management of mucosal oral cGvHD 
 
    
